Early prostate cancer antigen


Early prostate cancer antigen 2, EPCA-2 - a protein found in people with prostate cancer. Raising its level is a more sensitive and specific indicator of this cancer than PSA levels.

The presence of this protein has been confirmed several years ago, but was only able to be identified in prostate biopsy studies. Its presence was demonstrated by staining. Recently, methods have been developed to detect this protein in serum. In April 2007, the first report of a group of 330 patients was published, in which the EPCA-2 test allowed 90% of the respondents to identify prostate cancer patients. In cases where the cancer is spread beyond the gland, the sensitivity increases to 98%. A negative result with a sensitivity of 97% excludes the presence of cancer.

In the United States, procedures have been launched to approve this diagnostic approach by the Food and Drug Administration. Because of its greater sensitivity compared to PSA, which may also increase with inflammatory prostaglandin, it will allow better selection of patients who need prostate biopsy.

See terms related to medical terms and related wikipedia.

wiki

Comments

Popular posts from this blog

Association of Jewish handicrafts "Jad Charuzim"

Grouping Red Arrows

Catechism of Polish Child